Primary prevention of sudden death with implantable defibrillator therapy in patients with cardiac disease: Can we afford to do it? (Can we afford not to?)

Circulation

Volumn 104, Issue 13, 2001, Pages 1564-1570

  Exner, D V ^a   Klein, G J ^a   Prystowsky, E N ^a  

^a NONE   (Canada)

Author keywords

Cardiac arrest; Cost effectiveness; Heart failure; Myocardial infarction; Prevention

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; HEART DISEASE; HIGH RISK POPULATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LONG QT SYNDROME; MULTICENTER STUDY; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH; TREATMENT INDICATION;

EID: 0035949614     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc3801.096395     Document Type: Review

References (50)

1. Sudden cardiac death: Epidemiology, transient risk, and intervention assessment
2. Sudden cardiac death
3. Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases
4. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure
5. Late complications in patients with pectoral defibrillator implants with transvenous defibrillator lead systems: High incidence of insulation breakdown
6. Implantable cardioverter-defibrillator: A Volkswagen or a Rolls Royce: How much will we pay to save a life?
7. Detection of myocardial injury during transvenous implantation of automatic cardioverter-defibrillators
8. Gross and microscopic pathological changes associated with nonthoracotomy implantable defibrillator leads
9. Effects of antiarrhythmic medication on implantable cardioverter- defibrillator function
10. Expensive medical technologies and "indication extrapolation": The case of implantable cardioverter-defibrillators
11. Management of ventricular arrhythmias: Detection, drugs, and devices
12. Interpretation of outcomes of-antiarrhythmic clinical trials: Design features and population impact
13. Coronary heart disease mortality and sudden death: Trends and patterns in 35- to 44-year-old white males, 1970-1990
14. Sudden death vigorous exercise A study of 60 deaths associated with squash
15. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
16. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators
17. Improving survival from sudden cardiac arrest: The role of the automated external defibrillator
18. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
19. Canadian Implantable Defibrillator Study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone
20. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH)
21. The implantable cardioverter-defibrillator
22. Statistical aspects of early termination in the beta-blocker heart attack trial
23. Economic outcomes of implantable cardioverter-defibrillators
24. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias: AVID Investigators: Antiarrhythmics Versus Implantable Defibrillators
25. Subgroup analysis and other (mis)uses of baseline data in clinical trials
26. Cost-effectiveness of the implantable cardioverter-defibrillator: Results from the Canadian Implantable Defibrillator Study (CIDS)
27. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: The Canadian Implantable Defibrillator Study
28. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia: Multicenter Automatic Defibrillator Implantation Trial Investigators
29. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery: Coronary Artery Bypass Graft (CABG) Patch Trial Investigators
30. A randomized study of the prevention of sudden death in patients with coronary artery disease: Multicenter Unsustained Tachycardia Trial Investigators
31. The cost-effectiveness of automatic implantable cardiac defibrillators: Results from MADIT: Multicenter Automatic Defibrillator Implantation Trial
32. Implantable cardioverter defibrillator therapy: The sickest patients benefit the most
33. Can the MADIT results be applied in myocardial infarction patients at hospital discharge?
34. Mechanisms of death in the CABG patch trial: A randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery
35. Role of myocardial revascularization in sudden cardiac death
36. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome
37. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy
38. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy
39. Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large non-referral-based patient population
40. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy
41. Randomized, controlled trials, observational studies, and the hierarchy of research designs
42. A comparison of observational studies and randomized, controlled trials
43. ACC/AHA Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation)
44. Long-term follow-up of patients with long-QT syndrome treated with β-blockers and continuous pacing
45. Influence of genotype on the clinical course of the long-QT syndrome: International Long-QT Syndrome Registry Research Group
46. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy
47. Randomized trials or observational tribulations?
48. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II
49. ICD replacement: A family-based medicine approach
50. Beta-Blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: The Antiarrhythmics Versus Implantable Defibrillators (AVID) trial